Payment overview · 2025
General Payments
$184.94
11 reported records · 7 companies
Healthcare provider profile · identity verified
Matthew R Williams, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPRINGFIELD, MO · NPI 1184121998
Verified facts
What the public records show
CMS Open Payments records show Matthew R Williams, MD received $184.94 in general payments during 2025 across 11 reported records.
Lilly USA, LLC accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $67.44 | 36.5% | 3 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $22.70 | 12.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.68 | 11.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.67 | 10.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.65 | 10.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.31 | 9.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.49 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $184.94 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $44.09 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $22.70 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 202 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 165 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
198 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
202 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
165 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 925 | 284 |
| Levothyroxine Sodium | Levothyroxine Sodium | 533 | 161 |
| Lisinopril | Lisinopril | 528 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 511 | 158 |
| Trazodone Hcl | Trazodone Hcl | 433 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 390 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 383 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 367 | 116 |
| Gabapentin | Gabapentin | 350 | 89 |
| Furosemide | Furosemide | 290 | 87 |
| Tramadol Hcl | Tramadol Hcl | 284 | 81 |
| Sertraline Hcl | Sertraline Hcl | 276 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 270 | 77 |
| Losartan Potassium | Losartan Potassium | 268 | 91 |
| Omeprazole | Omeprazole | 266 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 251 | 80 |
| Metformin Hcl Er | Metformin Hcl | 250 | 72 |
| Fluticasone Propionate | Fluticasone Propionate | 244 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 73 |
| Montelukast Sodium | Montelukast Sodium | 243 | 60 |
| Tizanidine Hcl | Tizanidine Hcl | 232 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 80 |
| Mounjaro | Tirzepatide | 202 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 57 |
| Metformin Hcl | Metformin Hcl | 199 | 63 |
| Jardiance | Empagliflozin | 198 | 49 |
| Carvedilol | Carvedilol | 167 | 46 |
| Ozempic | Semaglutide | 165 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 154 | 58 |
| Potassium Chloride | Potassium Chloride | 144 | 47 |
| Buspirone Hcl | Buspirone Hcl | 142 | 40 |
| Meloxicam | Meloxicam | 139 | 41 |
| Famotidine | Famotidine | 137 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 130 | 38 |
| Alendronate Sodium | Alendronate Sodium | 126 | 36 |
| Ezetimibe | Ezetimibe | 124 | 34 |
| Alprazolam | Alprazolam | 121 | 56 |
| Simvastatin | Simvastatin | 111 | 34 |
| Xarelto | Rivaroxaban | 109 | 19 |
| Glimepiride | Glimepiride | 108 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 32 |
| Eliquis | Apixaban | 99 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 29 |
| Pregabalin | Pregabalin | 96 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 92 | 32 |
| Allopurinol | Allopurinol | 91 | 26 |
| Finasteride | Finasteride | 89 | 27 |
| Repatha Sureclick | Evolocumab | 88 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 82 | 19 |
| Irbesartan | Irbesartan | 81 | 23 |
| Nifedipine Er | Nifedipine | 81 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 67 | 16 |
| Spironolactone | Spironolactone | 65 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 19 |
| Warfarin Sodium | Warfarin Sodium | 62 | 23 |
| Januvia | Sitagliptin Phosphate | 61 | suppressed |
| Ondansetron Odt | Ondansetron | 59 | 19 |
| Cefdinir | Cefdinir | 57 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 46 |
| Baclofen | Baclofen | 54 | 11 |
| Clonidine Hcl | Clonidine Hcl | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 45 | 45 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | 13 |
| Meclizine Hcl | Meclizine Hcl | 42 | 17 |
| Memantine Hcl | Memantine Hcl | 42 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 37 | 37 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Klor-Con M20 | Potassium Chloride | 37 | 11 |
| Primidone | Primidone | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Atenolol | Atenolol | 34 | 12 |
| Azithromycin | Azithromycin | 34 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 20 |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | 13 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Prednisone | Prednisone | 31 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 21 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | 11 |
| Diazepam | Diazepam | 23 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 22 |
| Glipizide | Glipizide | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 16 |
| Scopolamine | Scopolamine | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | 11 |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Nystatin | Nystatin | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $184.94 · 11 records | Lilly USA, LLC | Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE, KISUNLA, LEQVIO, MOUNJARO, Ozempic, SMARTVEST | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error